Nasdaq · Common stock
Apnimed (APMD)
$18.95 −$0.04 (−0.21%)
- Day’s range
- $18.40–$19.52
- Volume
- 178,504
APMD price history
APMD closed at $18.95 on Oct. 26, 2026. Over the past year, its daily close ranged from $16.60 on Oct. 19, 2026 to $32.55 on Aug. 17, 2026.
Data table: APMD daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $18.95 |
| Oct. 23, 2026 | $18.99 |
| Oct. 22, 2026 | $18.53 |
| Oct. 21, 2026 | $18.90 |
| Oct. 20, 2026 | $18.51 |
| Oct. 19, 2026 | $16.60 |
| Oct. 16, 2026 | $17.76 |
| Oct. 15, 2026 | $18.25 |
| Oct. 14, 2026 | $17.23 |
| Oct. 13, 2026 | $17.83 |
| Oct. 12, 2026 | $18.63 |
| Oct. 9, 2026 | $18.52 |
| Oct. 8, 2026 | $18.22 |
| Oct. 7, 2026 | $18.04 |
| Oct. 6, 2026 | $18.65 |
| Oct. 5, 2026 | $21.75 |
| Oct. 2, 2026 | $21.51 |
| Oct. 1, 2026 | $22.54 |
| Sept. 30, 2026 | $21.91 |
| Sept. 29, 2026 | $23.90 |
| Sept. 28, 2026 | $21.67 |
| Sept. 25, 2026 | $21.09 |
| Sept. 24, 2026 | $21.63 |
| Sept. 23, 2026 | $22.49 |
| Sept. 22, 2026 | $25.51 |
| Sept. 21, 2026 | $26.22 |
| Sept. 18, 2026 | $29.00 |
| Sept. 17, 2026 | $28.11 |
| Sept. 16, 2026 | $27.09 |
| Sept. 15, 2026 | $25.56 |
| Sept. 14, 2026 | $25.55 |
| Sept. 11, 2026 | $26.23 |
| Sept. 10, 2026 | $26.80 |
| Sept. 9, 2026 | $28.08 |
| Sept. 8, 2026 | $28.79 |
| Sept. 4, 2026 | $27.45 |
| Sept. 3, 2026 | $27.81 |
| Sept. 2, 2026 | $27.83 |
| Sept. 1, 2026 | $26.85 |
| Aug. 31, 2026 | $26.25 |
| Aug. 28, 2026 | $29.71 |
| Aug. 27, 2026 | $28.72 |
| Aug. 26, 2026 | $29.58 |
| Aug. 25, 2026 | $27.37 |
| Aug. 24, 2026 | $25.63 |
| Aug. 21, 2026 | $28.03 |
| Aug. 20, 2026 | $28.55 |
| Aug. 19, 2026 | $32.03 |
| Aug. 18, 2026 | $31.81 |
| Aug. 17, 2026 | $32.55 |
| Aug. 14, 2026 | $31.75 |
| Aug. 13, 2026 | $28.79 |
| Aug. 12, 2026 | $26.65 |
| Aug. 11, 2026 | $24.87 |
| Aug. 10, 2026 | $27.94 |
| Aug. 7, 2026 | $27.00 |
| Aug. 6, 2026 | $27.88 |
| Aug. 5, 2026 | $26.51 |
| Aug. 4, 2026 | $25.71 |
| Aug. 3, 2026 | $25.00 |
| July 31, 2026 | $25.00 |
Key figures
- Average daily volume
- 506,091Past 3 months
- Market value
- $788.9M
- Dividend yield
- —
Price change
- 1 month
- −10.15%
What Wall Street says about APMD
In the past 90 days, Wall Street firms published 4 rating or price-target actions on APMD: 4 new ratings.
| Action | Rating | |||
|---|---|---|---|---|
| B of A Securities | Initiates coverage | Buy | $41 | |
| Cantor Fitzgerald | Initiates coverage | Overweight | $60 | |
| Evercore ISI Group | Initiates coverage | Outperform | — | |
| LifeSci Capital | Initiates coverage | Outperform | $50 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Apnimed, Inc. Common Stock
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
- Headquarters
- Cambridge, Mass.
- Listed
- July 31, 2026
- Sector
- Health care
- Industry
- Pharmaceutical preparations
In WallStreetDigest editions
No WallStreetDigest article about APMD is on the site yet.